Finished product reference
Iobenguane (Sup131/Supi)
Injection, Solution · Parenteral · 50 mCi
- List code
- 51084
- Pharmacologic class
- Radiopharmaceutical: iodine-131-labelled iobenguane (meta-iodobenzylguanidine, MIBG)
What it is and how it works
Iobenguane is a guanethidine analogue structurally similar to noradrenaline that is taken up by the noradrenaline transporter and stored in neurosecretory granules of adrenergic tissue. When labelled with iodine-131 it concentrates in neuroendocrine tumours, allowing scintigraphic imaging at diagnostic activities and delivering targeted beta radiation at therapeutic activities.
Indications
Diagnostic scintigraphy for localisation of phaeochromocytoma, paraganglioma, neuroblastoma and other neural crest tumours; at higher activities, targeted radionuclide therapy of inoperable MIBG-avid phaeochromocytoma, paraganglioma, neuroblastoma and carcinoid tumours.
Dosage and administration (summary)
Administered by slow intravenous injection or infusion in a nuclear medicine facility; activity is individualised according to the diagnostic or therapeutic protocol. Thyroid blockade with potassium iodide is started before and continued after administration.
Contraindications
Pregnancy and breast-feeding; hypersensitivity. For therapy: severe renal impairment or significant bone-marrow suppression, according to protocol.
Warnings and precautions
Many drugs (e.g. tricyclic antidepressants, labetalol, reserpine, sympathomimetics, some calcium-channel blockers and antipsychotics) reduce uptake and should be withdrawn beforehand where possible. Therapeutic doses may cause myelosuppression, hypothyroidism, nausea and, rarely, hypertensive crises; radiation-protection measures for patients, carers and staff are required. Rapid injection may cause transient hypertension.
Pregnancy
Contraindicated in pregnancy; pregnancy should be excluded before administration.
Storage and supply
Store in lead shielding according to the manufacturer’s instructions and national radiation-protection regulations; therapeutic preparations are often supplied frozen.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.